Progress of CDK4/6 inhibitors in treatment of hormone receptor-positive and human epithelial growth factor receptor 2-negative breast cancer
10.3760/cma.j.cn115355-20230109-00014
- VernacularTitle:CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性乳腺癌的研究进展
- Author:
Xin LI
1
;
Huayi ZHANG
;
Donghai LI
;
Le WANG
;
Kailin YANG
;
Gang GUO
Author Information
1. 内蒙古医科大学附属医院甲状腺乳腺外科，呼和浩特 010010
- Keywords:
Breast neoplasms;
Hormone receptor;
Human epithelial growth factor receptor 2;
Cyclin-dependent kinase 4/6 inhibitors
- From:
Cancer Research and Clinic
2023;35(9):713-716
- CountryChina
- Language:Chinese
-
Abstract:
Cyclin-dependent kinase (CDK)4/6 inhibitors combined with traditional endocrine therapy can significantly improve the progression-free survival and overall survival of hormone receptor-positive and human epithelial growth factor receptor 2-negative breast cancer patients. But different drugs, dosage and medication cycle will also bring different efficacy and safety incidents to patients. At the same time, confirming whether CDK4/6 inhibitors are equally applicable to Chinese breast cancer patients is not only an academic hotspot concerned by domestic clinicians, but also a practical need in actual diagnosis and treatment. This article reviews the classic clinical trials of drugs and the latest research progress.
